Mixed Hormone Receptor (ER+/PR- Or ER-/PR+) Breast Cancer

Detailed information on mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis, based on the latest scientific studies.

Loss of PR reduces the ESR1 expression in hormone-deprived T47D breast

Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer - ScienceDirect

Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands

Proposed treatment for patients with HER2-positive breast cancer

Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer

Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells - ScienceDirect

Schematic figure summarizing breast cancer subtypes based on their

The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer - Modern Pathology

Cancers, Free Full-Text

Putative risk classi fi cation scheme for estrogen receptor (ER)

Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer

Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival - ScienceDirect

Crosstalk between ER and HER family receptors. ER, estrogen receptor;